Literature DB >> 14718808

Time-resolved magnetic resonance angiography as a noninvasive method to characterize endoleaks: initial results compared with conventional angiography.

Robert A Lookstein1, Jeffrey Goldman, Lev Pukin, Michael L Marin.   

Abstract

PURPOSE: Several types of endoleaks have been described, each with different methods of treatment. Conventional arteriography is widely regarded as the gold standard for the classification of endoleaks. Recently, faster magnetic resonance gradients have allowed for rapid data acquisition and review of vascular studies as a real-time continuous angiogram (time resolved magnetic resonance angiography [TR-MRA]). This study was performed to compare the findings of TR-MRA with conventional angiography for the characterization of endoleaks.
METHODS: Between June 2002 and June 2003, 12 patients with documented endoleaks following endovascular repair of aortic aneurysms (10 abdominal and two thoracic) underwent TR-MRA to identify and characterize the endoleak. All patients had nitinol-based aortic stent grafts. MRA was performed on a 1.5-Tesla magnet (Sonata class; Siemens Medical Systems, Iselin, NJ). The TR-MRA studies were reviewed under continuous observation as a "cine MR angiogram." These MRA data sets were used to classify the endoleaks into types 1 through 3. The patients underwent conventional angiography following the MRA to confirm the findings and to plan treatment. The MRA findings were compared with the findings made at conventional arteriography.
RESULTS: TR-MRA identified seven patients with type 1 leaks, including four proximal and three distal. Four patients had type 2 leaks, including two arising from the inferior mesenteric artery and two from an iliolumbar artery. One patient had a type 3 leak. Conventional angiography confirmed the type of endoleak in all 12 patients.
CONCLUSION: These initial results demonstrate TR-MRA to be an effective noninvasive method for classifying endoleaks. This technique may allow for screening of patients with endoleaks to identify those requiring urgent repair.

Entities:  

Mesh:

Year:  2004        PMID: 14718808     DOI: 10.1016/j.jvs.2003.09.035

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  8 in total

1.  Endovascular therapy for thoracic aortic aneurysms: state of the art in 2012.

Authors:  Nicolas A Brozzi; Eric E Roselli
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-04

Review 2.  Surveillance Imaging Following Endovascular Aneurysm Repair.

Authors:  Nirnimesh Pandey; Harold I Litt
Journal:  Semin Intervent Radiol       Date:  2015-09       Impact factor: 1.513

Review 3.  Endoleakage after endovascular treatment of abdominal aortic aneurysms: Diagnosis, significance and treatment.

Authors:  Jafar Golzarian; David Valenti
Journal:  Eur Radiol       Date:  2006-04-11       Impact factor: 5.315

4.  Non-contrast MR imaging for detecting endoleak after abdominal endovascular aortic repair.

Authors:  Elda C Resta; Francesco Secchi; Antonello Giardino; Veronica G Nardella; Giovanni Di Leo; Nicola Flor; Francesco Sardanelli
Journal:  Int J Cardiovasc Imaging       Date:  2012-05-16       Impact factor: 2.357

5.  Importance of dynamic aortic evaluation in planning TEVAR.

Authors:  Guido H W van Bogerijen; Joost A van Herwaarden; Michele Conti; Ferdinando Auricchio; Vincenzo Rampoldi; Santi Trimarchi; Frans L Moll
Journal:  Ann Cardiothorac Surg       Date:  2014-05

6.  Imaging Surveillance following Endovascular Aneurysm Repair.

Authors:  Anand Shah; S William Stavropoulos
Journal:  Semin Intervent Radiol       Date:  2009-03       Impact factor: 1.513

Review 7.  Endovascular treatment of abdominal aortic aneurysms.

Authors:  Dominique B Buck; Joost A van Herwaarden; Marc L Schermerhorn; Frans L Moll
Journal:  Nat Rev Cardiol       Date:  2013-12-17       Impact factor: 32.419

8.  Abdominal aortic aneurysm: Treatment options, image visualizations and follow-up procedures.

Authors:  Zhong-Hua Sun
Journal:  J Geriatr Cardiol       Date:  2012-03       Impact factor: 3.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.